These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8786726)

  • 1. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.
    Breum L; Bjerre U; Bak JF; Jacobsen S; Astrup A
    Metabolism; 1995 Dec; 44(12):1570-6. PubMed ID: 8786726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
    Maheux P; Ducros F; Bourque J; Garon J; Chiasson JL
    Int J Obes Relat Metab Disord; 1997 Feb; 21(2):97-102. PubMed ID: 9043962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.
    Damsbo P; Hermann LS; Vaag A; Hother-Nielsen O; Beck-Nielsen H
    Diabetes Care; 1998 Sep; 21(9):1489-94. PubMed ID: 9727896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired activation of skeletal muscle glycogen synthase in non-insulin-dependent diabetes mellitus is unrelated to the degree of obesity.
    Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
    Metabolism; 1991 Mar; 40(3):252-60. PubMed ID: 1900343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
    Tong PC; Lee ZS; Sea MM; Chow CC; Ko GT; Chan WB; So WY; Ma RC; Ozaki R; Woo J; Cockram CS; Chan JC
    Arch Intern Med; 2002 Nov; 162(21):2428-35. PubMed ID: 12437401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo insulin action and muscle glycogen synthase activity in type 2 (non-insulin-dependent) diabetes mellitus: effects of diet treatment.
    Bak JF; Møller N; Schmitz O; Saaek A; Pedersen O
    Diabetologia; 1992 Aug; 35(8):777-84. PubMed ID: 1511806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular glucose metabolism after long term metabolic control with glyburide: improved glucose oxidation with unchanged glycogen synthase activity.
    Suh KI; Murata C; Song YM; Joyce M; Gumbiner B; Ditzler TM; Henry RR
    J Clin Endocrinol Metab; 1993 Aug; 77(2):464-70. PubMed ID: 8345053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
    Daubresse JC; Kolanowski J; Krzentowski G; Kutnowski M; Scheen A; Van Gaal L
    Obes Res; 1996 Jul; 4(4):391-6. PubMed ID: 8822764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals.
    Potter van Loon BJ; Radder JK; Frölich M; Krans HM; Zwinderman AH; Meinders AE
    Int J Obes Relat Metab Disord; 1992 Feb; 16(2):79-85. PubMed ID: 1316330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in NIDDM.
    Wright KS; Beck-Nielsen H; Kolterman OG; Mandarino LJ
    Diabetes; 1988 Apr; 37(4):436-40. PubMed ID: 2837418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin receptor function and glycogen synthase activity in human skeletal muscle. Physiology and pathophysiology.
    Bak JF
    Dan Med Bull; 1994 Apr; 41(2):179-92. PubMed ID: 8039433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
    Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
    Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise with calorie restriction improves insulin sensitivity and glycogen synthase activity in obese postmenopausal women with impaired glucose tolerance.
    Ryan AS; Ortmeyer HK; Sorkin JD
    Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E145-52. PubMed ID: 22008454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
    Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
    Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction.
    Van Gaal L
    Verh K Acad Geneeskd Belg; 1989; 51(1):47-80. PubMed ID: 2800685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography.
    Evans DJ; Murray R; Kissebah AH
    J Clin Invest; 1984 Oct; 74(4):1515-25. PubMed ID: 6148358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine: a novel approach to the treatment of type 2 diabetes.
    Pijl H; Ohashi S; Matsuda M; Miyazaki Y; Mahankali A; Kumar V; Pipek R; Iozzo P; Lancaster JL; Cincotta AH; DeFronzo RA
    Diabetes Care; 2000 Aug; 23(8):1154-61. PubMed ID: 10937514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.